Advertisement

Organisation › Details
Nouscom (Group)
Nouscom is a clinical-stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. Nouscom’s proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and clinically demonstrated to safely and potently harness the power of the immune system. Nouscom is currently advancing the clinical development of its wholly owned programs: > NOUS-209, an off-the-shelf cancer immunotherapy for the treatment of MSI solid tumors in combination with pembrolizumab in randomized Phase 2 trials. > NOUS-209, an off-the-shelf monotherapy in Lynch Syndrome carriers with the potential to ‘intercept cancer’ before it occurs. A Phase 1b is being conducted under a clinical trial collaboration and supply agreement signed in 2022 with the National Cancer Institute (NCI). > NOUS-PEV, a personalized cancer immunotherapy, is expected to enter randomized Phase 2 trials in indications with high unmet medical need in 2025. Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms sponsored by Janssen Research & Development and Bristol Myers Squibb. *
![]() |
Start | 2016-05-17 existent |
![]() |
Industry | cancer vaccine |
Industry 2 | drug development | |
![]() |
Person | Udier-Blagovic, Marina (Nouscom 202002– CEO joined 201609 as COO before Versant Ventures + Novartis + McKinsey) |
Person 2 | Muller, Tiffany (Nouscom 202407– promoted to CFO joined 2019 as VP Finance before Aramark) | |
![]() |
Region | Basel BS |
Country | Switzerland | |
Street | 18 Bäumleingasse | |
City | 4051 Basel | |
Tel | +41-61-201-1831 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Nouscom AG. (7/17/24). "Press Release: Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development". Basel. | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Nouscom (Group)
- [1] Nouscom S.r.l.. (12/3/24). "Press Release: Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer". Basel....
- [2] Nouscom AG. (7/17/24). "Press Release: Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development". Basel....
- [3] Angelini Ventures S.p.A.. (3/21/24). "Press Release: Angelini Ventures Invests into Extended €75.8 Million ($82 Mmillion) Series C Financing Round for Nouscom". Rome....
- [4] Nouscom AG. (11/14/23). "Press Release: Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round". Basel....
- [5] Nouscom AG. (5/17/22). "Press Release: Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed using Nouscom’s Proprietary Viral Vector Platform". Basel....
- [6] Nouscom AG. (12/11/20). "Press Release: Nouscom Appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer". Basel....
- [7] Nouscom AG. (2/26/20). "Press Release: Nouscom Strengthens Its Management Team. Marina Udier, PhD Appointed as Chief Executive Officer and Patricia Delaite, MD Appointed as Chief Medical Officer". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top